Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00189436Phase 4Completed

Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children

Role: lead

NCT00189475Phase 4Completed

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

Role: lead

NCT00189462Phase 4Completed

A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children

Role: lead

All 3 trials loaded